Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
C$2.10
-8.7%
C$2.06
C$1.02
C$30.90
C$90.42M1.365,416 shs193 shs
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$257.28
-1.0%
$236.74
$211.43
$387.99
$7.00B0.95334,558 shs22,512 shs
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
C$2.66
-1.1%
C$2.59
C$1.50
C$5.00
C$650.38M2.98,911 shs247 shs
ERGO
Entia Biosciences
$0.00
$0.00
$0.00
N/A16.6540 shsN/A
Sigilon Therapeutics, Inc. stock logo
SGTX
Sigilon Therapeutics
$22.47
$22.02
$3.77
$28.00
$56.40M4.1262,902 shsN/A
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
+12.20%+93.28%-4.96%-20.96%-92.41%
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
+3.02%+3.59%+13.12%+6.17%-7.09%
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
+1.89%-20.88%+3.46%+58.24%-40.22%
ERGO
Entia Biosciences
0.00%0.00%0.00%0.00%0.00%
Sigilon Therapeutics, Inc. stock logo
SGTX
Sigilon Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
4.499 of 5 stars
2.45.00.04.21.92.51.9
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
N/AN/AN/AN/AN/AN/AN/AN/A
ERGO
Entia Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Sigilon Therapeutics, Inc. stock logo
SGTX
Sigilon Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
4.00
Strong BuyN/AN/A
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
2.75
Moderate Buy$324.2526.03% Upside
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
0.00
N/AN/AN/A
ERGO
Entia Biosciences
0.00
N/AN/AN/A
Sigilon Therapeutics, Inc. stock logo
SGTX
Sigilon Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest BU, SGTX, APS, ERGO, and BIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/9/2025
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$260.00 ➝ $245.00
5/2/2025
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$355.00 ➝ $310.00
5/2/2025
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$400.00 ➝ $350.00
5/2/2025
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$409.00 ➝ $392.00
4/17/2025
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$320.00 ➝ $270.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
N/AN/AC$1.31 per share1.60C($0.92) per shareN/A
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$2.54B2.76$10.57 per share24.35$234.52 per share1.10
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
C$724.40K897.83C$0.07 per share39.00C$0.02 per share108.34
ERGO
Entia Biosciences
N/AN/AN/AN/AN/AN/A
Sigilon Therapeutics, Inc. stock logo
SGTX
Sigilon Therapeutics
$12.94M4.36N/AN/A$15.68 per share1.43
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
-C$154.69M-C$5.02N/AN/AN/A1,017.48%-136.29%N/A
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
-$1.84B-$76.20N/A20.67N/A-85.16%4.32%3.03%7/30/2025 (Estimated)
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
-C$12.74M-C$0.06N/AN/A-1,758.62%-185.21%-39.22%N/A
ERGO
Entia Biosciences
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Sigilon Therapeutics, Inc. stock logo
SGTX
Sigilon Therapeutics
-$43.56M-$12.23N/AN/AN/A-171.29%-83.07%-38.17%N/A

Latest BU, SGTX, APS, ERGO, and BIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$1.98N/AN/AN/AN/AN/A
5/1/2025Q1 2025
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$1.73$2.54+$0.81$2.29$573.01 million$585.40 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
N/A0.39%N/AN/AN/A
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
N/AN/AN/AN/AN/A
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
N/A4.45%N/AN/AN/A
ERGO
Entia Biosciences
N/AN/AN/AN/AN/A
Sigilon Therapeutics, Inc. stock logo
SGTX
Sigilon Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
-117.37
1.05
5.41
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
0.18
5.99
4.43
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
187.90
5.63
1.71
ERGO
Entia Biosciences
N/AN/AN/A
Sigilon Therapeutics, Inc. stock logo
SGTX
Sigilon Therapeutics
N/A
1.78
1.78
CompanyEmployeesShares OutstandingFree FloatOptionable
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
3143.06 millionN/ANot Optionable
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
7,70027.21 million22.57 millionOptionable
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
20244.51 millionN/ANot Optionable
ERGO
Entia Biosciences
6N/AN/ANot Optionable
Sigilon Therapeutics, Inc. stock logo
SGTX
Sigilon Therapeutics
622.51 million2.35 millionNot Optionable

Recent News About These Companies

Lilly & Co Eli's Net Worth
MCRB Seres Therapeutics, Inc.
Beam Therapeutics Inc.
Eli Lilly Concludes Acquisition Of Sigilon Therapeutics
Lilly Completes Acquisition of Sigilon Therapeutics
SGTX - Sigilon Therapeutics, Inc.
Eli Lilly and Company: Lilly to Acquire Sigilon Therapeutics

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aptose Biosciences stock logo

Aptose Biosciences TSE:APS

C$2.10 -0.20 (-8.70%)
As of 09:30 AM Eastern

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Bio-Rad Laboratories stock logo

Bio-Rad Laboratories NYSE:BIO

$257.28 -2.60 (-1.00%)
As of 10:16 AM Eastern

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Burcon NutraScience stock logo

Burcon NutraScience TSE:BU

C$2.66 -0.03 (-1.12%)
As of 09:30 AM Eastern

Burcon NutraScience Corporation, together with its subsidiaries, develops plant proteins and ingredients for use in the food and beverage industries in Canada. The company offers Peazazz and Peazac, a pea protein for use in dairy alternatives, ready-to-drink beverages, dry blended beverages, bars, baked goods, and meat substitute products. It provides Puratein, a canola protein isolate for use in meat alternatives, such as burgers, sausages, and nutrition bars; Supertein, a canola protein that is a light-colored powder for use in non-dairy frozen desserts, egg alternative, plant-based marshmallows and ready-to-mix beverages, whipped toppings, and plant-based bars; and Nutratein, a canola protein comprising a mixture of globulin and albumin proteins for use in meat and egg alternatives, and other plant-based functional foods. In addition, the company offers Nutratein-PS, a blend of Peazazz pea protein and Supertein canola protein; Nutratein-TZ, a blend of Peazac pea protein and Puratein canola protein; and CLARISOY, a soy protein for use in sports nutrition beverages, citrus-based drinks, fruit-flavored beverages, lemonades, powdered beverage mixes, and non-beverage plant-based products. The company was formerly known as Burcon Capital Corp. and changed its name to Burcon NutraScience Corporation in October 1999. The company was incorporated in 1998 and is headquartered in Vancouver, Canada.

Entia Biosciences OTCMKTS:ERGO

Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.

Sigilon Therapeutics stock logo

Sigilon Therapeutics NASDAQ:SGTX

Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.